Literature DB >> 19028417

Aurora-A interacts with Cyclin B1 and enhances its stability.

Lili Qin1, Tong Tong, Yongmei Song, Liyan Xue, Feiyue Fan, Qimin Zhan.   

Abstract

The mitotic regulator Aurora-A is an oncogenic protein that is over-expressed in many types of human tumors. However, the underlying mechanism through which Aurora-A promotes tumorigenesis remains unclear. Here, we show that overexpression of Aurora-A causes an elevation of Cyclin B1 expression. Cyclin B1 degradation is delayed in Aurora-A over-expressing cells, which depends on Aurora-A kinase activity. In contrast, Aurora-A RNAi enhances Cyclin B1 degradation. Furthermore, we found that Aurora-A interacts with Cyclin B1, and that Aurora-A overexpression reduces the interaction of Cyclin B1 with APC subunits. In human esophageal squamous cell carcinomas (ESCC), overexpression of Aurora-A was correlated with deregulated expression of Cyclin B1. Taken together, these findings suggest that overexpression of Aurora-A may stabilize Cyclin B1 through inhibiting its degradation. These results provide new insight into the mechanism of how deregulated Aurora-A contributes to genomic instability and carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028417     DOI: 10.1016/j.canlet.2008.10.011

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  18 in total

1.  The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.

Authors:  Vikas Sehdev; DunFa Peng; Mohammed Soutto; M Kay Washington; Frank Revetta; Jeffrey Ecsedy; Alexander Zaika; Tilman T Rau; Regine Schneider-Stock; Abbes Belkhiri; Wael El-Rifai
Journal:  Mol Cancer Ther       Date:  2012-02-01       Impact factor: 6.261

2.  Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.

Authors:  Norman L Lehman; James P O'Donnell; Lisa J Whiteley; Robert T Stapp; Trang D Lehman; Kathleen M Roszka; Lonni R Schultz; Caitlin J Williams; Tom Mikkelsen; Stephen L Brown; Jeffrey A Ecsedy; Laila M Poisson
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

3.  The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.

Authors:  Vikas Sehdev; Ahmed Katsha; Jeffrey Ecsedy; Alexander Zaika; Abbes Belkhiri; Wael El-Rifai
Journal:  Cancer       Date:  2012-09-12       Impact factor: 6.860

4.  Prognostic value of proliferation markers expression in breast cancer.

Authors:  Natalija Dedić Plavetić; Jasminka Jakić-Razumović; Ana Kulić; Damir Vrbanec
Journal:  Med Oncol       Date:  2013-03-07       Impact factor: 3.064

5.  Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome function.

Authors:  Natalia Filippova; Xiuhua Yang; Peter King; L Burt Nabors
Journal:  J Biol Chem       Date:  2012-07-24       Impact factor: 5.157

6.  VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma.

Authors:  Yan Li; Zhong-Fa Zhang; Jindong Chen; Dan Huang; Yan Ding; Min-Han Tan; Chao-Nan Qian; James H Resau; Hyung Kim; Bin Tean Teh
Journal:  Am J Transl Res       Date:  2010-05-20       Impact factor: 4.060

7.  USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase.

Authors:  S Giovinazzi; V M Morozov; M K Summers; W C Reinhold; A M Ishov
Journal:  Cell Death Differ       Date:  2013-01-25       Impact factor: 15.828

8.  Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma.

Authors:  James R Van Brocklyn; Jeffrey Wojton; Walter H Meisen; David A Kellough; Jeffery A Ecsedy; Balveen Kaur; Norman L Lehman
Journal:  Cancer Res       Date:  2014-08-08       Impact factor: 12.701

9.  The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.

Authors:  Xin Hong; James P O'Donnell; Clarence R Salazar; James R Van Brocklyn; Kahlil D Barnett; Dennis K Pearl; Ana C deCarvalho; Jeffrey A Ecsedy; Stephen L Brown; Tom Mikkelsen; Norman L Lehman
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-14       Impact factor: 3.333

Review 10.  Aurora-A: a potential DNA repair modulator.

Authors:  Yan Wang; Huizhen Sun; Ziliang Wang; Mingming Liu; Zihao Qi; Jiao Meng; Jianmin Sun; Gong Yang
Journal:  Tumour Biol       Date:  2013-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.